



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 19 Jul 2021 (#22)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-DA-21-002](#) Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research. The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of National Institute on Drug Abuse ([NIDA](#)) -supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a U.S.-based institution and a scientist working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science. This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.

- [PA-20-183](#): NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#): NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-200](#): NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#): NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-272](#): Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

[NOT-NS-22-003](#) Notice of Special Interest: Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders. Gastrointestinal (GI) complications in children and adults with neurodevelopmental disorders have drawn attention to gaps in understanding their causes and treatment. GI dysfunction is particularly common in individuals with neurodevelopmental disorders such as autism, Fragile X syndrome, and Rett syndrome, as well as chromosomal disorders such as Down syndrome. GI disorders in these conditions can include gut malformations present at birth (such as pyloric stenosis or Hirschsprung disease) but also functional issues such as

feeding problems, gastro-esophageal reflux disease (GERD), cyclic vomiting, delayed gastric emptying, diarrhea, bloating, celiac disease, irritable bowel symptoms, and constipation leading to encopresis, incontinence, and stool impaction. These GI issues may be associated with severe nutritional deficiencies, weight loss, and failure to thrive. GI symptoms are reported in between 23-70% of individuals with autism, a rate ~ 8 times higher than in the general population, with similar rates in individuals with other less common forms of intellectual and developmental disabilities (IDD) (Holingue et al., Autism Res 2018:11:24-36). Unfortunately, mechanisms to accurately diagnose GI conditions in this population are limited, and tailored treatments to address them are almost nonexistent, particularly since clinical trials for IDD populations are rare. This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through July 16, 2024. Submit applications for this initiative using one of the following funding opportunity announcements:

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Funding Opportunity Announcements (FOA)

1. Elucidating the Roles of Transposable Elements in AD/ABDR and Aging (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-22-021](#)

Type: R01

Application Due Date: November 02, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to support hypothesis-driven research to gain an understanding of the dysregulation of transposable elements (TE) and their contributions to Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ABDR) and aging. This FOA encourages applications that investigate causal effects of TE activation in disease and aging and applications that model therapeutic interventions to facilitate the transition of the field from observational discovery towards a deeper mechanistic understanding of the function and regulation of TEs.

Budget: NIA intends to commit \$9,500,000 in FY 2022 to fund 13-18 awards: 10-13 awards in AD/ABDR and 3-5 awards in aging research. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimer's Disease and Related Dementias (R61/R33 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-22-024](#)

Type: R61/R33

Application Due Date: October 20, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support research that can lead to the development of evidence-based primary care screening tools and behavioral interventions to prevent abuse in at-risk older and vulnerable adults with mild cognitive impairment (MCI) and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ABDR) and their families. Specifically, this FOA invites R61/R33 applications proposing Stage I screening and behavioral intervention development and Stage III efficacy trials in primary care settings. Studies must directly address the priority research needs and gaps highlighted in the U.S. Preventive Services Task Force's 2018 final recommendation statement on [Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening](#) for the development and validation of the following:

1. Reliable and accurate screening instruments or assessments in primary care settings for older and vulnerable adults without recognized signs or symptoms of abuse (i.e., asymptomatic), and for their medical visit companions, at the time of diagnosis of MCI or AD/ABDR and subsequent primary care encounters; and/or
2. Brief and effective point-of-care psychoeducational and behavioral interventions for the prevention of all types of abuse.

Budget: For the R61 phase, and pending annual appropriations, NIA intends to commit \$5.6 million in FY 2022 and in FY 2023 to fund 5-7 R61 awards. For the R33 phase, and pending annual appropriations, NIA intends to commit \$11.2 million in FY 2024, FY 2025, and FY 2026 to fund 5-7 R33 awards. Application budgets for the R61 and R33 phases must reflect the actual needs of the proposed project. For the R61 phase, the combined budget for direct costs may not exceed \$750,000, with no more than \$500,000 requested in any single year. For the R33 phase, if awarded, the combined budget for direct costs may not exceed \$3,000,000. The scope of the proposed project should determine the project period. The maximum project period is 5 years. The maximum project period for the R61 planning phase is two years. The maximum project period for the R33 phase is three years.

3. BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-21-205](#)

Type: R01

Application Due Date: October 13, 2021, October 11, 2022, October 11, 2023. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Guided by the goals established in [BRAIN 2025: A Scientific Vision](#) and reinforced by the [Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup](#), this Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This FOA encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this FOA are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.

Budget: Issuing IC and partner [components](#) intend to commit an estimated total of \$3 million in FY2022 to fund up to 8 awards. For future years the intended commitment will depend on annual appropriations. Application budgets are limited to \$300,000 in direct costs in any project year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105